Coherus Oncology, Inc. (CHRS) vs Oramed Pharmaceuticals Inc. (ORMP)
- Coherus Oncology, Inc. CHRS 1.00 −6.54%
- Oramed Pharmaceuticals Inc. ORMP 4.07 −2.63%
Coherus Oncology, Inc. and Oramed Pharmaceuticals Inc. are both Biotechnology companies. Coherus Oncology, Inc. and Oramed Pharmaceuticals Inc. are of similar size ($173.9M and $165.3M). Coherus Oncology, Inc. has negative trailing earnings, so its P/E is not meaningful; Oramed Pharmaceuticals Inc. trades at 1.0×. Oramed Pharmaceuticals Inc. grew revenue faster over the last twelve months: 347.8% against 61.0%. Oramed Pharmaceuticals Inc. has the higher net margin (0.00% vs −259.4%) and the lower return on invested capital (−3.40% vs 0.00%). Across the 19 metrics below, Oramed Pharmaceuticals Inc. leads on 12 and Coherus Oncology, Inc. on 7.
Valuation
Profitability
| Metric | CHRS | ORMP | Biotechnology median |
|---|---|---|---|
| Gross margin | 68.94% | 32.31% | 65.16% |
| Operating margin | (311.56%) | 0.00% | 0.00% |
| Net margin | (259.41%) | 0.00% | 0.00% |
| Free cash flow margin | (365.22%) | 0.00% | 0.00% |
| Return on equity | (146.27%) | 73.90% | (56.36%) |
| Return on assets | (41.90%) | 65.52% | (48.04%) |
| Return on invested capital | 0.00% | (3.40%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack